<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/621CACAB-53EE-48C8-A5EF-69DA4FA58943"><gtr:id>621CACAB-53EE-48C8-A5EF-69DA4FA58943</gtr:id><gtr:name>Leibniz Association</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name><gtr:address><gtr:line1>BBSRC</gtr:line1><gtr:line2>Polaris House</gtr:line2><gtr:line3>North Star Avenue</gtr:line3><gtr:line4>Swindon</gtr:line4><gtr:postCode>SN2 1UH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name><gtr:address><gtr:line1>BBSRC</gtr:line1><gtr:line2>Polaris House</gtr:line2><gtr:line3>North Star Avenue</gtr:line3><gtr:line4>Swindon</gtr:line4><gtr:postCode>SN2 1UH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/621CACAB-53EE-48C8-A5EF-69DA4FA58943"><gtr:id>621CACAB-53EE-48C8-A5EF-69DA4FA58943</gtr:id><gtr:name>Leibniz Association</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8B8EA445-E75D-4708-972F-A10DF88F5961"><gtr:id>8B8EA445-E75D-4708-972F-A10DF88F5961</gtr:id><gtr:firstName>Douglas</gtr:firstName><gtr:otherNames>Bruce</gtr:otherNames><gtr:surname>Kell</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_qA137293"><gtr:id>3EE86F7B-BFF4-4D26-A104-C3171E4ECE7D</gtr:id><gtr:title>LINK Grant Prof Kell - Applied Genomics Programme</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_qA137293</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Special Contribution: LINK Grant Prof Kell: An emerging trend in biology is the ability to measure most of the chemical substances at a particular level of organisation (e.g. all the RNA molecules or all the proteins). The level of metabolism is downstream from these, many arguments, indicate that the metabolome should be a particularly high resolution method for amplifying and thereby reflecting changes in the levels of gene products, especially those which accompany disease pathogenesis. A key imperative is therefore to develop and industrialise the technology optimal for determining the serum metabolome reliably, to establish the disease-independent ranges of the many hundreds of metabolites that can be observed with such technology, to recognise the disease-independent changes that occur simply as a function of diet, gender, age, therapeutic interventions and lifestyle. Although there are increasingly well-established data on the content and dynamic range of the human serum proteome, no such catalogue yet exists for the equivalent metabolome. Primary metabolism of majormetabolites whose concentration ranges down to lM probably involves ~1,000 metabolites of MW &amp;lt; 1000.By using a battery of modern analytical methods (GCxGC-tof, LC-ESI-MS, FTIR, FTICR-MS, NMR) we expect to see the overwhelming majority of the relevant metabolites. By measuring the serum metabolome we shall generate the baseline data necessary to determine how this changes under normal conditions. This will be compared with the equivalent data from patients suffering from two specific diseases (Alzheimers disease and ovarian cancer) as a means to obtaining an early indication of the effectiveness of treatment and progression of disease. In Alzheimers disease, there is a pressing clinical need to develop a biomarker which is accurate in differentiating between early Alzheimers disease and normal ageing, and will predict response to anti-Alzheimer drugs. Also, it will be important to establish whether biomarkers change during the course of illness, which will shed light on the pathophysiology of the disease and may lead to new treatments. In ovarian cancer it will be of particular clinical importance to characterise and validate markers that can be used to predict or assess response in patients treated with specific chemotherapeutic drugs. This would benefit both the patients, so that ineffective and/or toxic drugs can be changed before the patient has deteriorated beyond the point of further treatment, and the health service through the cessation of ineffective but costly drugs at an early stage.</gtr:technicalSummary><gtr:fund><gtr:end>2010-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>838082</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Volatile organic compound analysis for CAP</gtr:description><gtr:id>946602B6-E045-4436-8BBD-AEFA6458FD1E</gtr:id><gtr:impact>Work is still in progress; have generted an approach for analysis of breath.</gtr:impact><gtr:outcomeId>YZ1tbKmcMiU-1</gtr:outcomeId><gtr:piContribution>Chemometric analysis of VOC analysed by GC-MS</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leibniz Association</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>German Institute of Human Nutrition (DIfE)</gtr:department><gtr:description>Serum metabolomics for diabetes</gtr:description><gtr:id>3319AEC1-6CEF-4C1E-A4E5-F3ECCE9C3731</gtr:id><gtr:impact>in progress</gtr:impact><gtr:outcomeId>ENQVS1Gpkn7-1</gtr:outcomeId><gtr:piContribution>UPLC-MS analysis of serum
chemometrics on data generated</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Metabolomics of asthma</gtr:description><gtr:id>1D461605-28BA-4BCA-9D98-8A88265E018C</gtr:id><gtr:impact>Chemometric process in place for data deconvolution
Analysis of asthma samples still ongoing</gtr:impact><gtr:outcomeId>CDfBrCtwa3q-1</gtr:outcomeId><gtr:piContribution>Chemometrics on volatile organic compounds collected from breath</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>School visits</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>4A4A4777-28FF-4FD1-9CD0-3DEF2E4DF612</gtr:id><gtr:impact>Four PhD students within the group take part in Schools visits and going out to Schools to highlight chemistry

Hopefully more interest in reading a science degree at University</gtr:impact><gtr:outcomeId>k3sfUKYH5d2</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>SET (science engineering technology)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>28359407-9647-497F-82F9-B641309F9289</gtr:id><gtr:impact>3 PhD students tool posters to SET in Houses of Commons

Interaction with parliamentarians</gtr:impact><gtr:outcomeId>NfiDuMYGoNe</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lab work experience</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>06F9C3FC-5BB3-4E8D-BE2E-2E4530680DEE</gtr:id><gtr:impact>3 pupils from High Schools have had work experience in the laboratory

Pupils gained experience of working in a research laboratory</gtr:impact><gtr:outcomeId>idzeAcKfK9r</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2008,2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>580000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>project grant; The Sarcolemmal Calcium Signalling Protein PMCA4 as a Novel Target to Reduce Cardiac Hypertrophy and Failure</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>E8EC14BF-10DB-4CDC-9F1B-0E71B3FEFCA8</gtr:id><gtr:outcomeId>kaMN2LiXByb0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>project grant; Assessment of potential therapies for pre-eclampsia and fetal growth restriction using murine models</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>412814E5-D67B-4733-B6F8-1D2F80185857</gtr:id><gtr:outcomeId>dFjfQtQ54Eh0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>75000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>project grant; Metabolomic analysis of myocardial infarction and reperfusion; a first step towards a novel insight into metabolic processes underlying arrhythmogenesis/Manchester Biomedical Research Centre</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>CEC7AF4D-7D36-4959-B8DA-33F8E471CB57</gtr:id><gtr:outcomeId>FZJhmm1XBLq0</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1236000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>project grant; Metabolomics and Proteomics initiative from Cancer Research UK, Wolfson Clinical Research Infrastructure Grant</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>F1D19CFE-BC44-4861-A59B-F7DC1613D60A</gtr:id><gtr:outcomeId>B9iu2UL16Rs0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>705000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>prpject grant; The development of a metabolite biomarker-based screening test to predict pre-eclampsia</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>A5E3534B-277D-48C6-8AB1-DAA608E62CD4</gtr:id><gtr:outcomeId>kjA3s7EeTyW0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>project grant; A Metabolomic analysis of adverse cardiac remodelling following myocardial infarction; a first step towards identification of a clinical biomarker</gtr:description><gtr:fundingOrg>Johnson &amp; Johnson</gtr:fundingOrg><gtr:id>85F83CC6-0CB5-4BA6-9A0D-026B5592A10E</gtr:id><gtr:outcomeId>LuiuXDLDtTd0</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sysmo Data Management Group</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>68EE44B9-5F7F-4F51-98F1-47F38F7A3117</gtr:id><gtr:impact>Goodacre is part of BBSRC's Sysmo Data Management Group.</gtr:impact><gtr:outcomeId>dhMCLyRuZsG</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Metabolomics Standards Iniative</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>708B3351-1E71-4289-A0C8-CCF0103D986A</gtr:id><gtr:impact>Goodacre, Broadhurst, Nicholls formed part of the Metabalomics Standards Initiative: msi-workgroups.sourceforge.net</gtr:impact><gtr:outcomeId>CvLw5axbeRV</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Ministerial Lectures to GPs and surgeons</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>5DF6F49E-E291-4B33-BC4E-8EB5C52AE990</gtr:id><gtr:impact>Roy Goodacre also gave two Invited Ministerial Lecture to GPs and surgeons in Italy: Lezioni sulla Medicina della Complessit&amp;agrave;. 28 October 2008. Catania, Sicily, Italy; Aspetti Metabolici e Clinici nella Practica Medica. 30 October 2008. Trapani, Sicily, Italy.</gtr:impact><gtr:outcomeId>gwWN6GryRFL</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Husermet data base with metadata and analytical data from normal populations (n=2000) will be made available 31 Dec 2011 as agreed with the SAC. This will be accessible via: www.husermet.org</gtr:description><gtr:id>16E5356D-98DE-4922-ADC5-1BE78D5A6C63</gtr:id><gtr:impact>Metabolomics resource for normal populations will act as baseline data for disease and nutritional studies</gtr:impact><gtr:outcomeId>NHL7GcX1Hcw</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Husermet database</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:url>http://www.husermet.org</gtr:url><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Standard Operating Procedures (SOPs) have been generated and put in place from sample curation, sample collection, sample analysis, and data analysis. The SOPs for sample preparation and analysis have been adopted by GlaxoSmithKline.</gtr:description><gtr:id>38550840-5649-47E5-83F0-63808BC8441B</gtr:id><gtr:impact>Standard Operating Procedures (SOPs) for metabolomics accepted elsewhere. 
These have been published:
Sample collection - Dunn et al. (2008) Int. J. Epidemiol. 37, i23-i30. 
Optimisation of UPLC-MS - Zelena et al. (2009) Anal. Chem. 81, 1357-64
Optimisation of GC-MS - Begley et al. (2009) Anal. Chem. 81, 7038-7046
MS deconvolution - Dunn et al. (2008) J. Chromat B. 871, 288-298.
GC-MS/UPLC-MS metabolite identification - Brown et al. (2009) Analyst 134,1322-32</gtr:impact><gtr:outcomeId>ZBqP4MSNboq</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>SOP development for metabolomics from human biofluids</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7F5EC513-415D-4459-AE0A-3DFC43EE48AF</gtr:id><gtr:title>Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry.</gtr:title><gtr:parentPublicationTitle>Nature protocols</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb85a17d93275235cf967f6a6e2bf664"><gtr:id>cb85a17d93275235cf967f6a6e2bf664</gtr:id><gtr:otherNames>Dunn WB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1750-2799</gtr:issn><gtr:outcomeId>csD7q7MrHYR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C23784E-6C12-46EB-ACEF-21996F1E5A06</gtr:id><gtr:title>A novel untargeted metabolomics correlation-based network analysis incorporating human metabolic reconstructions.</gtr:title><gtr:parentPublicationTitle>BMC systems biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/27e82b90f83933ecf134e4105478f138"><gtr:id>27e82b90f83933ecf134e4105478f138</gtr:id><gtr:otherNames>Kotze HL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1752-0509</gtr:issn><gtr:outcomeId>5461e0d0d63902.03285769</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC714492-DDD2-4AFF-9943-53C413929BB9</gtr:id><gtr:title>Detection and identification of novel metabolomic biomarkers in preeclampsia.</gtr:title><gtr:parentPublicationTitle>Reproductive sciences (Thousand Oaks, Calif.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c70c645110243cbee35121515ab2d29"><gtr:id>1c70c645110243cbee35121515ab2d29</gtr:id><gtr:otherNames>Kenny LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1933-7191</gtr:issn><gtr:outcomeId>CDmVYELCHDR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4209E444-7647-4D32-851A-B7E5759B1C10</gtr:id><gtr:title>A pragmatic and readily implemented quality control strategy for HPLC-MS and GC-MS-based metabonomic analysis.</gtr:title><gtr:parentPublicationTitle>The Analyst</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd6bbbe44f029c4869374eb8ab8ab24c"><gtr:id>dd6bbbe44f029c4869374eb8ab8ab24c</gtr:id><gtr:otherNames>Sangster T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0003-2654</gtr:issn><gtr:outcomeId>E3SFusbDoQj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3266B22E-E673-4271-8DA7-3CF6C2E94193</gtr:id><gtr:title>Non-invasive metabolomic analysis of breath using differential mobility spectrometry in patients with chronic obstructive pulmonary disease and healthy smokers.</gtr:title><gtr:parentPublicationTitle>The Analyst</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0f15a4540d95954354aa5430d61ae09"><gtr:id>e0f15a4540d95954354aa5430d61ae09</gtr:id><gtr:otherNames>Basanta M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0003-2654</gtr:issn><gtr:outcomeId>iuMKC61xaKi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D5E1B89-424F-46AC-910C-C66514AF53E3</gtr:id><gtr:title>Systems biology, metabolic modelling and metabolomics in drug discovery and development.</gtr:title><gtr:parentPublicationTitle>Drug discovery today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81f12d897d5b95c253d7ff4b6000ede5"><gtr:id>81f12d897d5b95c253d7ff4b6000ede5</gtr:id><gtr:otherNames>Kell DB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1359-6446</gtr:issn><gtr:outcomeId>euVpsPB9wH4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>33B4B71D-F95F-4270-BE8F-B2E661032AF8</gtr:id><gtr:title>Mass spectrometry tools and metabolite-specific databases for molecular identification in metabolomics.</gtr:title><gtr:parentPublicationTitle>The Analyst</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2df6cf0e44bda3035674f81d473ebf19"><gtr:id>2df6cf0e44bda3035674f81d473ebf19</gtr:id><gtr:otherNames>Brown M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0003-2654</gtr:issn><gtr:outcomeId>bttSHjtgj54</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1BD5D1B7-D724-4588-AB1A-907A359C74A7</gtr:id><gtr:title>Facilitating the development of controlled vocabularies for metabolomics technologies with text mining.</gtr:title><gtr:parentPublicationTitle>BMC bioinformatics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b79d9264073630088f6b18d07cd57d6"><gtr:id>0b79d9264073630088f6b18d07cd57d6</gtr:id><gtr:otherNames>Spasic I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1471-2105</gtr:issn><gtr:outcomeId>jHFrxqhfv4o</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ACD97825-CCD1-4E60-9A1D-FF3C73E1DA13</gtr:id><gtr:title>The virtual human: towards a global systems biology of multiscale, distributed biochemical network models.</gtr:title><gtr:parentPublicationTitle>IUBMB life</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81f12d897d5b95c253d7ff4b6000ede5"><gtr:id>81f12d897d5b95c253d7ff4b6000ede5</gtr:id><gtr:otherNames>Kell DB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1521-6543</gtr:issn><gtr:outcomeId>UStaAzMxFRz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80749772-5C1C-4DE9-9677-5DEFB6E033E0</gtr:id><gtr:title>Multiobjective optimization in bioinformatics and computational biology.</gtr:title><gtr:parentPublicationTitle>IEEE/ACM transactions on computational biology and bioinformatics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cde640f9e1e59db151b0f1ad86463430"><gtr:id>cde640f9e1e59db151b0f1ad86463430</gtr:id><gtr:otherNames>Handl J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1545-5963</gtr:issn><gtr:outcomeId>GeFjvZnzrga</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C00948A8-2E48-4AB5-90DB-0CC25D231731</gtr:id><gtr:title>Taking your breath away: metabolomics breathes life in to personalized medicine.</gtr:title><gtr:parentPublicationTitle>Trends in biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5d8678c00941d46b959af6e027383e9"><gtr:id>d5d8678c00941d46b959af6e027383e9</gtr:id><gtr:otherNames>Rattray NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0167-7799</gtr:issn><gtr:outcomeId>5461e0d31743e3.87571181</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B53BECA2-F327-4F76-897F-70E16E858F64</gtr:id><gtr:title>COordination of Standards in MetabOlomicS (COSMOS): facilitating integrated metabolomics data access.</gtr:title><gtr:parentPublicationTitle>Metabolomics : Official journal of the Metabolomic Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dae631a3576f009bac122d1667e53a1d"><gtr:id>dae631a3576f009bac122d1667e53a1d</gtr:id><gtr:otherNames>Salek RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1573-3882</gtr:issn><gtr:outcomeId>56d8dc782c25e8.79634988</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1956D848-6FB2-44FD-97AE-4878C9F788C7</gtr:id><gtr:title>Molecular phenotyping of a UK population: defining the human serum metabolome.</gtr:title><gtr:parentPublicationTitle>Metabolomics : Official journal of the Metabolomic Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb85a17d93275235cf967f6a6e2bf664"><gtr:id>cb85a17d93275235cf967f6a6e2bf664</gtr:id><gtr:otherNames>Dunn WB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1573-3882</gtr:issn><gtr:outcomeId>5461da41f008d1.58018102</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53C9E8EF-A16A-4A3E-99B5-5DC389C46339</gtr:id><gtr:title>Development and performance of a gas chromatography-time-of-flight mass spectrometry analysis for large-scale nontargeted metabolomic studies of human serum.</gtr:title><gtr:parentPublicationTitle>Analytical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b8979275010abfc2685c77eca62a85d"><gtr:id>8b8979275010abfc2685c77eca62a85d</gtr:id><gtr:otherNames>Begley P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0003-2700</gtr:issn><gtr:outcomeId>Lq4f8rf9zDS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>19830937-09C5-430E-A7C2-A56FF487ED90</gtr:id><gtr:title>Changes in the metabolic footprint of placental explant-conditioned culture medium identifies metabolic disturbances related to hypoxia and pre-eclampsia.</gtr:title><gtr:parentPublicationTitle>Placenta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb85a17d93275235cf967f6a6e2bf664"><gtr:id>cb85a17d93275235cf967f6a6e2bf664</gtr:id><gtr:otherNames>Dunn WB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0143-4004</gtr:issn><gtr:outcomeId>pSZsLxHrg94</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2230FB96-21ED-42BC-B068-FD4FDE95E0C6</gtr:id><gtr:title>A metabolomics investigation into the effects of HIV protease inhibitors on HPV16 E6 expressing cervical carcinoma cells.</gtr:title><gtr:parentPublicationTitle>Molecular bioSystems</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c2188e89405bf6b4afb9f9f1a390482d"><gtr:id>c2188e89405bf6b4afb9f9f1a390482d</gtr:id><gtr:otherNames>Kim DH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1742-2051</gtr:issn><gtr:outcomeId>5461e0d10c9242.99172752</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D73D36B6-E85F-4166-96D4-51228EDB2915</gtr:id><gtr:title>Development of a robust and repeatable UPLC-MS method for the long-term metabolomic study of human serum.</gtr:title><gtr:parentPublicationTitle>Analytical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/22f5f547a5e2a0da7a5998e9b3a0d962"><gtr:id>22f5f547a5e2a0da7a5998e9b3a0d962</gtr:id><gtr:otherNames>Zelena E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0003-2700</gtr:issn><gtr:outcomeId>rLF9vRPX877</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B924BD8-9843-4DB2-9372-02CA59432D9D</gtr:id><gtr:title>Mass appeal: metabolite identification in mass spectrometry-focused untargeted metabolomics</gtr:title><gtr:parentPublicationTitle>Metabolomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b15b8175b2944a1871dc7f086d3a7a0f"><gtr:id>b15b8175b2944a1871dc7f086d3a7a0f</gtr:id><gtr:otherNames>Dunn W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>5461df8678e6f9.63640830</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8AF75D25-16AE-4D14-8245-8CD5645B2139</gtr:id><gtr:title>Serum metabolomics reveals many novel metabolic markers of heart failure, including pseudouridine and 2-oxoglutarate</gtr:title><gtr:parentPublicationTitle>Metabolomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b15b8175b2944a1871dc7f086d3a7a0f"><gtr:id>b15b8175b2944a1871dc7f086d3a7a0f</gtr:id><gtr:otherNames>Dunn W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:outcomeId>CWPaEyPtQ1N</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99171EB8-405F-4129-B84F-8460CDE48E1B</gtr:id><gtr:title>Erratum to: COordination of Standards in MetabOlomicS (COSMOS): facilitating integrated metabolomics data access</gtr:title><gtr:parentPublicationTitle>Metabolomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d92cf36c0bdb3d82360a12275653cef"><gtr:id>3d92cf36c0bdb3d82360a12275653cef</gtr:id><gtr:otherNames>Salek R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1573-3882</gtr:issn><gtr:outcomeId>56d8dc7920d112.54289812</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89ABD690-12CF-445D-92C6-DC3C9C770C1A</gtr:id><gtr:title>Statistical strategies for avoiding false discoveries in metabolomics and related experiments</gtr:title><gtr:parentPublicationTitle>Metabolomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f2a1d852b7601717f6d64aaec80b565"><gtr:id>5f2a1d852b7601717f6d64aaec80b565</gtr:id><gtr:otherNames>Broadhurst D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:outcomeId>rt98az9PTRK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CF27A24-ABCD-466A-A1FE-92A29AB83006</gtr:id><gtr:title>Integration of metabolomics in heart disease and diabetes research: current achievements and future outlook.</gtr:title><gtr:parentPublicationTitle>Bioanalysis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb85a17d93275235cf967f6a6e2bf664"><gtr:id>cb85a17d93275235cf967f6a6e2bf664</gtr:id><gtr:otherNames>Dunn WB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1757-6180</gtr:issn><gtr:outcomeId>Wvh53gCKS7D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA5864B4-EEE4-4B44-B17A-BD5C6CD7E544</gtr:id><gtr:title>Standard reporting requirements for biological samples in metabolomics experiments: mammalian/in&amp;nbsp;vivo experiments</gtr:title><gtr:parentPublicationTitle>Metabolomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/954d87bb5653f09b11cdfadd678ef439"><gtr:id>954d87bb5653f09b11cdfadd678ef439</gtr:id><gtr:otherNames>Griffin J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:outcomeId>dqD1nyNYyu3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B422C8FE-B3B7-4F78-B7FA-86B780E2A016</gtr:id><gtr:title>Theodor B&amp;uuml;cher Lecture. Metabolomics, modelling and machine learning in systems biology - towards an understanding of the languages of cells. Delivered on 3 July 2005 at the 30th FEBS Congress and the 9th IUBMB conference in Budapest.</gtr:title><gtr:parentPublicationTitle>The FEBS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81f12d897d5b95c253d7ff4b6000ede5"><gtr:id>81f12d897d5b95c253d7ff4b6000ede5</gtr:id><gtr:otherNames>Kell DB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1742-464X</gtr:issn><gtr:outcomeId>sZXdiB4My6j</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE7BD7D1-B545-478C-B250-A349C9A3241E</gtr:id><gtr:title>A GC-TOF-MS study of the stability of serum and urine metabolomes during the UK Biobank sample collection and preparation protocols.</gtr:title><gtr:parentPublicationTitle>International journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb85a17d93275235cf967f6a6e2bf664"><gtr:id>cb85a17d93275235cf967f6a6e2bf664</gtr:id><gtr:otherNames>Dunn WB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0300-5771</gtr:issn><gtr:outcomeId>LrJEweEx99c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90B1FCB5-877B-4FD1-898B-E9206325099F</gtr:id><gtr:title>MeMo: a hybrid SQL/XML approach to metabolomic data management for functional genomics.</gtr:title><gtr:parentPublicationTitle>BMC bioinformatics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b79d9264073630088f6b18d07cd57d6"><gtr:id>0b79d9264073630088f6b18d07cd57d6</gtr:id><gtr:otherNames>Spasic I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1471-2105</gtr:issn><gtr:outcomeId>rM7uzpyGU8d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>281DB185-96F1-4ED3-88B7-4E1F2BB18D55</gtr:id><gtr:title>Growth control of the eukaryote cell: a systems biology study in yeast.</gtr:title><gtr:parentPublicationTitle>Journal of biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1f4567421560a111836d33793ba7d7e8"><gtr:id>1f4567421560a111836d33793ba7d7e8</gtr:id><gtr:otherNames>Castrillo JI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1475-4924</gtr:issn><gtr:outcomeId>Mds64hXV1z8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04C36344-BCD3-46DE-AFFC-236AC996DD8F</gtr:id><gtr:title>The role of metabolites and metabolomics in clinically applicable biomarkers of disease.</gtr:title><gtr:parentPublicationTitle>Archives of toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b038e7ec85f23ad9e2ddad52c97f48f8"><gtr:id>b038e7ec85f23ad9e2ddad52c97f48f8</gtr:id><gtr:otherNames>Mamas M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0340-5761</gtr:issn><gtr:outcomeId>C6shw53UKGu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D833178-4015-442F-8EDF-E3FDEC786AA9</gtr:id><gtr:title>Comparative evaluation of software for deconvolution of metabolomics data based on GC-TOF-MS</gtr:title><gtr:parentPublicationTitle>TrAC Trends in Analytical Chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e96e84f01a13b8c22d773b0b45d3878"><gtr:id>6e96e84f01a13b8c22d773b0b45d3878</gtr:id><gtr:otherNames>Lu H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:outcomeId>frqVUuRscfs</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D9FAE2F-7FD8-4821-94B6-8761CE812DEA</gtr:id><gtr:title>Biomarkers of dietary energy restriction in women at increased risk of breast cancer.</gtr:title><gtr:parentPublicationTitle>Cancer prevention research (Philadelphia, Pa.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a89c875cdfe1b84604e9e1a7878c3878"><gtr:id>a89c875cdfe1b84604e9e1a7878c3878</gtr:id><gtr:otherNames>Ong KR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1940-6215</gtr:issn><gtr:outcomeId>ZL5FdmVLxvB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>737C784B-7EC0-4B5C-8841-A1FDC4F2664B</gtr:id><gtr:title>Metabolomics standards initiative: ontology working group work in progress</gtr:title><gtr:parentPublicationTitle>Metabolomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86091e0a2462ad1beb14a941f5980556"><gtr:id>86091e0a2462ad1beb14a941f5980556</gtr:id><gtr:otherNames>Sansone S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:outcomeId>BLMmQNboxwt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C018DC7C-D287-4075-9540-6C9D0CEE2916</gtr:id><gtr:title>Closed-loop, multiobjective optimization of two-dimensional gas chromatography/mass spectrometry for serum metabolomics.</gtr:title><gtr:parentPublicationTitle>Analytical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/26e1663aa1766d8e3995e64b08cf9279"><gtr:id>26e1663aa1766d8e3995e64b08cf9279</gtr:id><gtr:otherNames>O'Hagan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0003-2700</gtr:issn><gtr:outcomeId>PhtoFomNNWj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>097A7883-BEC0-4044-814F-CC6D123E0137</gtr:id><gtr:title>Metabolic footprinting as a tool for discriminating between brewing yeasts.</gtr:title><gtr:parentPublicationTitle>Yeast (Chichester, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a89c689b57155dbd2ae7713d07672e8"><gtr:id>4a89c689b57155dbd2ae7713d07672e8</gtr:id><gtr:otherNames>Pope GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0749-503X</gtr:issn><gtr:outcomeId>onFEzeStTVJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5EE801FF-6BB1-430B-B784-382C0BD970CF</gtr:id><gtr:title>Metabolomic biomarkers: search, discovery and validation.</gtr:title><gtr:parentPublicationTitle>Expert review of molecular diagnostics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81f12d897d5b95c253d7ff4b6000ede5"><gtr:id>81f12d897d5b95c253d7ff4b6000ede5</gtr:id><gtr:otherNames>Kell DB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1473-7159</gtr:issn><gtr:outcomeId>QYhytopZfCS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07BD67F5-EB37-4300-A55F-02734A66D503</gtr:id><gtr:title>Analysis of the metabolic footprint and tissue metabolome of placental villous explants cultured at different oxygen tensions reveals novel redox biomarkers.</gtr:title><gtr:parentPublicationTitle>Placenta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ad795f687a0d4ecde5d71e717f832b2"><gtr:id>3ad795f687a0d4ecde5d71e717f832b2</gtr:id><gtr:otherNames>Heazell AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0143-4004</gtr:issn><gtr:outcomeId>FhrqrMPjREe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55A11D84-8CB1-4E24-8BC8-4E933F47A0C0</gtr:id><gtr:title>Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy.</gtr:title><gtr:parentPublicationTitle>Chemical Society reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb85a17d93275235cf967f6a6e2bf664"><gtr:id>cb85a17d93275235cf967f6a6e2bf664</gtr:id><gtr:otherNames>Dunn WB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0306-0012</gtr:issn><gtr:outcomeId>jibv1vhqPgs</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>03C96A29-DD39-4B60-8A94-522466F45161</gtr:id><gtr:title>Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI).</gtr:title><gtr:parentPublicationTitle>Metabolomics : Official journal of the Metabolomic Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32dcee5e15ef80ee113a35a9068b269c"><gtr:id>32dcee5e15ef80ee113a35a9068b269c</gtr:id><gtr:otherNames>Sumner LW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1573-3882</gtr:issn><gtr:outcomeId>gmpf6ptm7DY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5197F12E-1281-45E9-813B-B6E203DB7FCB</gtr:id><gtr:title>Metabolite profiles of interacting mycelial fronts differ for pairings of the wood decay basidiomycete fungus, Stereum hirsutum with its competitors Coprinus micaceus and Coprinus disseminatus</gtr:title><gtr:parentPublicationTitle>Metabolomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/554f51441b8693be5089ede446385084"><gtr:id>554f51441b8693be5089ede446385084</gtr:id><gtr:otherNames>Peiris D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:outcomeId>sRbVPAjaBPJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4AC35560-BDEE-4C7E-9FD7-B48093E9C167</gtr:id><gtr:title>Automated workflows for accurate mass-based putative metabolite identification in LC/MS-derived metabolomic datasets.</gtr:title><gtr:parentPublicationTitle>Bioinformatics (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2df6cf0e44bda3035674f81d473ebf19"><gtr:id>2df6cf0e44bda3035674f81d473ebf19</gtr:id><gtr:otherNames>Brown M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1367-4803</gtr:issn><gtr:outcomeId>fHtGCQs2rkS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>347D978D-E786-445B-8A33-D3D746EC02A8</gtr:id><gtr:title>Proposed minimum reporting standards for data analysis in metabolomics</gtr:title><gtr:parentPublicationTitle>Metabolomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e1f45dc7da1034e88521bb6d0c328bb4"><gtr:id>e1f45dc7da1034e88521bb6d0c328bb4</gtr:id><gtr:otherNames>Goodacre R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:outcomeId>GtEkZrt68y7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18961B38-E83B-4E82-9745-9AA6065E290C</gtr:id><gtr:title>ParEGO: a hybrid algorithm with on-line landscape approximation for expensive multiobjective optimization problems</gtr:title><gtr:parentPublicationTitle>IEEE Transactions on Evolutionary Computation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/823200453d0ec7e569c6d19732945b63"><gtr:id>823200453d0ec7e569c6d19732945b63</gtr:id><gtr:otherNames>Knowles J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:outcomeId>BccULeSjZia</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_qA137293</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>